Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine.
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
21
06
2022
received:
13
12
2021
accepted:
24
06
2022
pubmed:
5
10
2022
medline:
18
11
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
Rivaroxaban (RIV; Xarelto; Janssen Pharmaceuticals, Beerse, Belgium) is one of the direct oral anticoagulants. The drug is a strong substrate of cytochrome P450 (CYP) enzymes and efflux transporters. This study aimed to develop a physiologically-based pharmacokinetic (PBPK) model for RIV. It contained three hepatic metabolizing enzyme reactions (CYP3A4, CYP2J2, and CYP-independent) and two active transporter-mediated transfers (P-gp and BCRP transporters). To illustrate the performance of the developed RIV PBPK model on the prediction of drug-drug interactions (DDIs), carbamazepine (CBZ) was selected as a case study due to the high DDI potential. Our study results showed that CBZ significantly reduces the exposure of RIV. The area under the concentration-time curve from zero to infinity (AUC
Identifiants
pubmed: 36193622
doi: 10.1002/psp4.12844
pmc: PMC9662201
doi:
Substances chimiques
Rivaroxaban
9NDF7JZ4M3
ATP Binding Cassette Transporter, Subfamily G, Member 2
0
Neoplasm Proteins
0
Cytochrome P-450 CYP3A
EC 1.14.14.1
Cytochrome P-450 Enzyme System
9035-51-2
Carbamazepine
33CM23913M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1430-1442Informations de copyright
© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Neurol Neurochir Pol. 2017 Mar - Apr;51(2):194-196
pubmed: 28215696
Postgrad Med J. 2006 Sep;82(971):568-72
pubmed: 16954451
Clin Pharmacokinet. 2014 Jan;53(1):89-102
pubmed: 23912563
Clin Pharmacokinet. 2014 Jan;53(1):1-16
pubmed: 23999929
Thromb J. 2018 Dec 04;16:32
pubmed: 30534008
Epilepsia. 1986 Jul-Aug;27(4):458-63
pubmed: 3720706
J Pharm Biomed Anal. 2013 Sep;83:279-85
pubmed: 23770783
Ther Drug Monit. 2009 Dec;31(6):764-8
pubmed: 19855315
Br J Clin Pharmacol. 2006 Aug;62(2):237-42
pubmed: 16842400
Expert Rev Clin Pharmacol. 2013 Mar;6(2):143-57
pubmed: 23473592
Acta Neurol Belg. 2009 Dec;109(4):271-6
pubmed: 20120206
Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70
pubmed: 22958812
Clin Pharmacol Ther. 2004 Sep;76(3):192-200
pubmed: 15371980
Curr Neuropharmacol. 2010 Sep;8(3):254-67
pubmed: 21358975
Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):183-191
pubmed: 28895074
Drug Metab Dispos. 2009 May;37(5):1056-64
pubmed: 19196845
BMC Med. 2016 Nov 29;14(1):191
pubmed: 27894343
Pharmaceutics. 2021 Feb 20;13(2):
pubmed: 33672439
Br J Clin Pharmacol. 2013 Sep;76(3):455-66
pubmed: 23305158
CPT Pharmacometrics Syst Pharmacol. 2022 Nov;11(11):1430-1442
pubmed: 36193622
J Clin Pharmacol. 2021 May;61(5):656-665
pubmed: 33205449
J Pharmacol Exp Ther. 2011 Jul;338(1):372-80
pubmed: 21515813
J Clin Pharmacol. 2021 Jun;61 Suppl 1:S70-S82
pubmed: 34185905
Br J Clin Pharmacol. 2009 Jul;68(1):77-88
pubmed: 19660005
J Clin Pharmacol. 2011 Aug;51(8):1233-6
pubmed: 21098143
Ned Tijdschr Geneeskd. 2013;157(52):A6568
pubmed: 24382036
Epilepsia. 2002 Apr;43(4):365-85
pubmed: 11952767
J Clin Pharm Ther. 2011 Apr;36(2):225-9
pubmed: 21366652
Drugs Aging. 2004;21(10):639-53
pubmed: 15287823
Thromb Res. 2011 Jun;127(6):497-504
pubmed: 20888031
Xenobiotica. 2005 Sep;35(9):891-910
pubmed: 16308283
Int J Clin Pharmacol Ther. 2013 Jul;51(7):549-61
pubmed: 23458226
Xenobiotica. 2007 Oct-Nov;37(10-11):1257-94
pubmed: 17968745
Ther Drug Monit. 2020 Feb;42(1):157-158
pubmed: 31725065
Clin Pharmacol Ther. 2005 Oct;78(4):412-21
pubmed: 16198660
Pharmaceutics. 2021 Feb 17;13(2):
pubmed: 33671323
Cardiovasc Drugs Ther. 2022 Feb;36(1):121-129
pubmed: 33411110